GNOM - Latest News

Global X - Genomics & Biotechnology ETF (GNOM), operates in Financial Services / Asset Management - Global, trades on NASDAQ.

Market capitalization stands near $85.4M, a proxy for assets under management on listed ETFs.

The article list below shows the most recent GNOM headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent GNOM Headlines

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next?

defenseworld.net - Aug 12, 2026

Global X Genomics and Biotechnology ETF (NASDAQ: GNOM - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesd

ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?

247wallst.com - Jul 21, 2026

The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.

How News Affects GNOM Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track GNOM's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked GNOM news questions

What is the latest GNOM news headline?

The most recent GNOM headline (Aug 12, 2026) is "Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the GNOM news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What GNOM news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual GNOM options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.